Search results
SPUTNIK LIGHT, THE FIRST COMPONENT OF SPUTNIK V, IS A SAFE AND EFFECTIVE STAND-ALONE ONE-SHOT VACCINE AGAINST COVID-19 AND AN IDEAL BOOSTER
Sputnik Light is a safe and approved stand-alone one-shot vaccine against COVID-19 created by The Gamaleya Center and RDIF (The Russian Direct Investment Fund) in Russia.
Nov 27, 2020 · Requests for more than 1.2 billion doses of Sputnik V vaccine came from more than 50 countries. The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.
Sputnik V is the world's first registered vaccine based on a well-studied human adenovirus vector platform. It has been approved for use in 71 countries with a total population of 4 billion people.
Sputnik V provides full protection against severe cases of COVID-19. Sputnik V guarantees robust humoral (antibodies which are first line of defense) and cell mediated (long term protection) immune response. The Phase III clinical trial results proved high levels of safety and immunogenicity of the Sputnik V vaccines including elderly group.
Feb 4, 2022 · Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for vaccine against COVID 19 RDIF Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).
Aug 25, 2021 · Moscow, August 25, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus in the Republic of Indonesia. Indonesia has become the 70th country in the world to register the Russian registered vaccine coronavirus RDIF.
Feb 19, 2021 · Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals; it is one of only three vaccines in the world with efficacy of over 90%; Sputnik V provides full protection against severe cases of COVID-19.
Mar 22, 2021 · The technology transfer is expected to be completed in the 2Q of 2021 followed by full-scale commercial production of Sputnik V. Virchow Biotech capacities will help facilitate global supply of Sputnik V to international partners of RDIF.
Feb 20, 2021 · Sputnik V granted emergency use authorization in Ghana. Moscow, February 20, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health of the Republic of Ghana.
